O'Toole David D

RCEL CFO O'Toole buys 1,800 shares at $4.78; stock +36.0% in 90 days but insider's prior trades at ticker 0-for-4 well-timed, company unprofitable.

CFO David D O'Toole purchased 1,800 shares of RCEL at $4.78 on 2026-03-11, adding 1.3% to holdings of 140,127 shares. While the stock has gained 36.0% over the past 90 days and currently trades at $4.80, his prior transaction history at RCEL provides limited confidence in timing insight: 4 prior measurable buys at this ticker yielded 0 outcomes with positive 90-day returns, with 90-day returns ranging from -34.6% to -17.0%. Separately, his cross-ticker track record shows 20 prior buys averaging +5.3% over 90 days with a 47.37% win rate, indicating modest baseline skill. The company itself remains unprofitable with a net loss of $13.2M against $17.1M quarterly revenue, which limits interpretation of the buy as a strong conviction signal.

CFO O'Toole buys 3,000 RCEL shares at $4.15; stock now $4.85. All 5 prior same-ticker buys generated negative 90d returns.

David D. O'Toole, CFO of AVITA Medical, purchased 3,000 shares at $4.15 on 2026-02-19, representing a 2.2% increase to his 140,127-share position. While the stock has risen 9.2% over the past 30 days and 29.3% over 90 days from lower base levels, his same-ticker history presents a notable pattern: all 5 prior buys at RCEL produced negative 90-day returns, ranging from -17.0% to -34.6%, with 0 of 5 classified as well-timed. The company remains unprofitable on a full-year basis with $-13.2M net income against $17.1M quarterly revenue. This repeated timing pattern at this specific ticker—coupled with ongoing losses—warrants examination of whether the CFO's purchase decisions have consistently preceded further declines.

CFO O'Toole bought 2,000 RCEL shares at $4.52; stock down 67.6% from 52-week high, 0 of 4 prior buys well-timed.

O'Toole David D, CFO of AVITA Medical, purchased 2,000 shares at $4.52 on 2025-08-26, adding 6.7% to his existing position. The purchase occurs with the stock trading 67.6% below its 52-week high and down 21.0% in the 30 days prior to the trade. At RCEL specifically, O'Toole's prior 4 measurable buys (spanning December 2024 through February 2025) showed 0 instances of positive 90-day returns, with cumulative losses ranging from -31.3% to -34.6% over the 90-day horizon. The company is currently unprofitable with a net income of $-9.9M against quarterly revenue of $18.4M, though annual revenue growth stands at 28.1%. The repeated purchase pattern at depressed valuations paired with consistent 90-day underperformance at this specific ticker suggests price weakness has persisted despite prior accumulation.

CFO O'Toole buys 2,000 RCEL shares at $4.81; all 5 prior RCEL buys by him posted negative 90d returns.

CFO David D O'Toole purchased 2,000 shares of AVITA Medical at $4.81 on 2025-08-12, raising his holdings to 29,657 shares. However, his transaction-timing record at this ticker is notably unfavorable: across his 5 prior purchases at RCEL, 0 of 5 delivered positive 90-day returns, with losses ranging from -1.0% to -34.6%. The current stock price of $5.52 is 60.7% below the 52-week high of $14.06, and AVITA is unprofitable with net income of $-9.9M against $18.4M quarterly revenue. This purchase follows a 17.5% decline over the prior 90 days and extends a pattern where the CFO's prior RCEL accumulations consistently underperformed within their post-purchase 90-day windows.

CFO O'Toole buys 1,000 RCEL shares at $9.90; stock down 45.7% from 52-week high despite +28.1% annual revenue growth.

O'Toole, the CFO, purchased 1,000 shares of AVITA Medical on 2025-02-20 at $9.90, following a similar purchase the prior day. His same-ticker trading record at RCEL shows mixed timing: 1 of 2 measurable prior buys generated a positive 90-day return (+5.9%), while the other declined -1.0%. The current share price of $9.95 sits 45.7% below the 52-week high of $18.31, despite the company posting annual revenue growth of +28.1%. However, AVITA remains unprofitable (net income of $-16.2M on quarterly revenue of $19.5M), and the stock has fallen 25.4% over the past 90 days. The timing and scale of this purchase occur against deteriorating recent price momentum, even as the company continues to grow revenue.

CFO O'Toole buys 1,000 RCEL shares at $10.25; stock down 44.2% from 52-week high, company unprofitable with $-16.2M net loss.

David D O'Toole, CFO of AVITA Medical, purchased 1,000 shares at $10.25 on 2025-02-19, raising his holdings to 24,734 shares. The transaction occurred as RCEL trades -44.2% from its 52-week high of $18.31, following a 90-day decline of -20.6%, despite a +18.2% rebound over the prior 30 days. O'Toole's cross-ticker track record shows mixed outcomes—20 prior buys averaged only +0.4% over 30 days and +6.9% over 90 days with a 50% win rate—while his same-ticker history at RCEL is notably weak, with only 1 of 5 prior measurable transactions yielding a positive 90-day return. The company remains fundamentally challenged: most recent quarter revenue of $19,546,000.00 fell below operating losses of $-16,205,000.00, and the full fiscal year was unprofitable, even as annual revenue grew +28.1%. This purchase occurs in a depressed price environment with a track record of mistimed entries at this specific ticker, warranting investor scrutiny of the company's path to profitability.

CFO David O'Toole buys 975 RCEL shares for $12,151.75 at $12.46 average; mixed track record at this ticker and cross-ticker context

David D O'Toole, CFO of AVITA Medical, purchased 975 shares across 2 separate transactions on 2024-12-05 for a blended average price of $12.46, increasing his holdings by 4.3% to 23,734 shares post-transaction. At the same-ticker level, his prior 5 buys at RCEL show a split record: 2 of 5 were well-timed at the 90-day mark (including a +32.0% return from a 2023-12-12 buy), but 3 of 5 delivered negative or significantly underwater 90-day outcomes (including two consecutive February 2024 buys that each lost over 50% within 90 days). His cross-ticker track record shows an avg 90d return of +5.0% across 19 prior buys with a 47.37% win rate. The company remains unprofitable (latest quarter net income -$16.2M despite revenue growth of +45.7%), and the stock is -32.1% from its 52-week high of $18.31, though it has recovered +9.1% over the last 30 days. The modest purchase size relative to his existing stake and the lack of any scheduled-trading plan disclosure suggest this is a discretionary open-market decision, though the execution across two distinct price points ($12.53 and $12.40) and the timing relative to recent price momentum warrant monitoring.